Among patients who became aPL-negative, the cumulative incidence of recurrent thrombosis did not differ before aPL-negativization (HR 0.52, 95%CI 0.26–1.06) but dropped by 88% after aPL-negativization (HR 0.12, 95%CI 0.05–0.58), even after adjusting for age, primary APS and type of initial thrombosis (P = 0.006). This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.